The complaint filed against the NASDAQ-listed company alleges that PROCEPT BioRobotics utilized aggressive discounting strategies to pull sales forward from future periods. By inflating revenue figures through these practices, the firm reportedly created a significant inventory glut, rendering its public financial disclosures throughout the class period materially misleading. Shareholders seeking to participate in the recovery effort do not need to serve as lead plaintiffs to remain eligible for potential damages.

Legal counsel from the DJS Law Group is currently soliciting contact from affected investors to discuss the appointment of a lead plaintiff. The lawsuit cites specific violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, alongside SEC Rule 10b-5. Those who incurred financial losses during the specified period are encouraged to reach out to the firm's Eastchester, New York office to evaluate their legal standing in the case.